JP2019503355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019503355A5 JP2019503355A5 JP2018532421A JP2018532421A JP2019503355A5 JP 2019503355 A5 JP2019503355 A5 JP 2019503355A5 JP 2018532421 A JP2018532421 A JP 2018532421A JP 2018532421 A JP2018532421 A JP 2018532421A JP 2019503355 A5 JP2019503355 A5 JP 2019503355A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- composition
- use according
- inflammation
- cd11b
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 11
- 206010061218 Inflammation Diseases 0.000 claims 8
- 230000004054 inflammatory process Effects 0.000 claims 8
- 102100019441 ITGAM Human genes 0.000 claims 4
- 101710006572 ITGAM Proteins 0.000 claims 4
- 102100001475 ITGB2 Human genes 0.000 claims 4
- 101710006663 ITGB2 Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 4
- 102000016550 Complement Factor H Human genes 0.000 claims 3
- 108010053085 Complement Factor H Proteins 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 3
- 102000004965 antibodies Human genes 0.000 claims 3
- 108090001123 antibodies Proteins 0.000 claims 3
- 210000002864 mononuclear phagocyte Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 2
- 208000002780 Macular Degeneration Diseases 0.000 claims 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 2
- 230000002207 retinal Effects 0.000 claims 2
- 235000020945 retinal Nutrition 0.000 claims 2
- 239000011604 retinal Substances 0.000 claims 2
- 229950004292 Erlizumab Drugs 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
Claims (15)
- 炎症の治療に使用するための、CD11b/CD18に対する補体因子Hの結合を阻害する薬剤を含む組成物。
- 前記薬剤が、CD11b/CD18に結合する、請求項1に記載の使用のための薬剤を含む組成物。
- 前記薬剤が、抗体である、請求項1または2に記載の使用のための薬剤を含む組成物。
- 前記薬剤が、クローン5C6およびクローンICRF44を含む群から選択される抗CD11b抗体である、請求項2または3に記載の使用のための薬剤を含む組成物。
- 前記薬剤が、エルリズマブ(erlizumab)およびクローンL130を含む群から選択される抗CD18抗体である、請求項2または3に記載の使用のための薬剤を含む組成物。
- 前記薬剤が、小分子である、請求項1または2に記載の使用のための薬剤を含む組成物。
- 前記炎症が、単核食細胞の蓄積に関連する、請求項1〜6のいずれか1項に記載の使用のための薬剤を含む組成物。
- 前記単核食細胞の蓄積に関連する炎症が、網膜の炎症、神経変性疾患、および代謝障害を含む群から選択される、請求項7に記載の使用のための薬剤を含む組成物。
- 前記単核食細胞の蓄積に関連する炎症が、網膜の炎症である、請求項7または8に記載の使用のための薬剤を含む組成物。
- 前記炎症が、加齢黄斑変性である、請求項1〜9のいずれか1項に記載の使用のための薬剤を含む組成物。
- 前記薬剤が、前記対象に局所投与される、請求項1〜10のいずれか1項に記載の使用のための薬剤を含む組成物。
- CD11b/CD18に対する補体因子Hの結合を阻害する薬剤と少なくとも1つの薬学的に許容可能な賦形剤とを含む医薬組成物。
- CD11b/CD18に対する補体因子Hの結合を阻害する薬剤を含む薬物。
- 炎症、好ましくは加齢黄斑変性の治療に使用するための、請求項12に記載の医薬組成物または請求項13に記載の薬物。
- 請求項1〜11のいずれか1項に記載の薬剤、請求項12もしくは14に記載の医薬組成物、または請求項13もしくは14に記載の薬物を含む、キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15202603.5 | 2015-12-23 | ||
EP15202603 | 2015-12-23 | ||
PCT/EP2016/082540 WO2017109164A1 (en) | 2015-12-23 | 2016-12-23 | AGENTS THAT INHIBIT THE BINDING OF CFH TO CD11b/CD18 AND USES THEREOF |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019503355A JP2019503355A (ja) | 2019-02-07 |
JP2019503355A5 true JP2019503355A5 (ja) | 2020-02-06 |
JP7199966B2 JP7199966B2 (ja) | 2023-01-06 |
Family
ID=55068856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018532421A Active JP7199966B2 (ja) | 2015-12-23 | 2016-12-23 | CD11b/CD18に対するCFHの結合を阻害する薬剤、およびその使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11072661B2 (ja) |
EP (1) | EP3394100A1 (ja) |
JP (1) | JP7199966B2 (ja) |
CA (1) | CA3009553A1 (ja) |
WO (1) | WO2017109164A1 (ja) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8726230D0 (en) | 1987-11-10 | 1987-12-16 | Rosen H | Antibodies |
US5462990A (en) * | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
ATE180408T1 (de) * | 1991-10-04 | 1999-06-15 | Us Health | Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen |
US6670321B1 (en) * | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
US6974815B2 (en) | 2002-10-11 | 2005-12-13 | Bristol-Myers Squibb Company | Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents |
AU2006214320C1 (en) | 2005-02-14 | 2012-07-05 | University Of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
EP1739078A1 (de) * | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
BRPI0619657A2 (pt) * | 2005-11-04 | 2011-11-08 | Genentech Inc | métodos de prevenção ou melhoria de doença ocular, uso de um inibidor de complemento, uso de um sirna especìfico para uma proteìna do sistema complemento e uso de um ácido nucleico que codifica um inibidor do sistema complemento |
EP2479284B1 (en) | 2006-07-13 | 2017-09-20 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
WO2009015183A1 (en) * | 2007-07-23 | 2009-01-29 | University Of Utah Research Foundation | Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
EP2563359A1 (en) | 2010-04-30 | 2013-03-06 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
DK2909232T3 (da) | 2012-10-17 | 2020-06-08 | Inst Nat Sante Rech Med | Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af aldersrelateret makuladegeneration (amd) |
WO2014127064A2 (en) * | 2013-02-12 | 2014-08-21 | The Trustees Of Columbia University In The City Of New York | Rage as a c1q receptor, methods and applications |
EP2898896A1 (en) | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
WO2015120130A1 (en) | 2014-02-07 | 2015-08-13 | Novartis Ag | Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy |
-
2016
- 2016-12-23 US US16/066,015 patent/US11072661B2/en active Active
- 2016-12-23 EP EP16819574.1A patent/EP3394100A1/en active Pending
- 2016-12-23 JP JP2018532421A patent/JP7199966B2/ja active Active
- 2016-12-23 CA CA3009553A patent/CA3009553A1/en active Pending
- 2016-12-23 WO PCT/EP2016/082540 patent/WO2017109164A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014518275A5 (ja) | ||
WO2017132432A8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
JP2016535777A5 (ja) | ||
PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
WO2008154251A4 (en) | C3b antibodies and methods for the prevention and treatment of complement- associated disorders | |
JP2012193216A5 (ja) | ||
JP2013538796A5 (ja) | ||
JP2013520405A5 (ja) | ||
JP2017506624A5 (ja) | ||
BR112017022568A2 (pt) | compostos e seus usos como inibidores de bace1 | |
WO2015171965A3 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
JP2019524822A5 (ja) | ||
JP2016503010A5 (ja) | ||
WO2015138628A8 (en) | Use of aav-expressed m013 protein as an anti-inflammatory therapeutic | |
AU2018264384A1 (en) | Solid forms of berberine ursodeoxycholate and compositions and methods thereof | |
JP2017503014A5 (ja) | ||
RU2013154699A (ru) | Сцилло-инозитол для применения в лечении поведенческих и психических расстройств | |
MX2021002321A (es) | Nuevos metodos. | |
MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
JP2016512817A5 (ja) | ||
JP2018529666A5 (ja) | ||
WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
JP2019518022A5 (ja) | ||
RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
WO2018005801A3 (en) | Novel non-systemic tgr5 agonists |